Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for Cholangiocarcinoma.

ABSTRACT:

Importance

Since fibroblast growth factor receptor inhibitors (FGFRi) are used for treatment of intrahepatic cholangiocarcinoma (iCCA), understanding potential complications following longer-term use in clinical practice settings is warranted. This study describes cataract formation or progression as a complication of FGFRi use for the treatment of iCCA, even after treatment discontinuation.

Objective

To describe cases of cataract formation or worsening in patients with iCCA treated with FGFRi and to characterize the ophthalmologic features, risk factors, and outcomes for FGFRi-associated cataracts.

Design, setting, and participants

This retrospective case series study used data from patients with iCCA harboring FGFR2 aberrations who received FGFRi in clinical trials

SUBMITTER: Kassaye I 

PROVIDER: S-EPMC11581600 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature